Cellid, Co., Ltd. (KOSDAQ:299660)
South Korea
· Delayed Price · Currency is KRW 3,330.00
-80.00 (-2.35%)
At close: Dec 5, 2025
Cellid, Company Description
Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies.
It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) and prostate-specific membrane (PSMA) antigens.
The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; BVAC-Neo.
Cellid, Co., Ltd. was founded in 2006 and is headquartered in Seoul, South Korea.
Cellid, Co., Ltd.
| Country | South Korea |
| Founded | 2006 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| CEO | Yuil Kang Chang |
Contact Details
Address: 142 dong Seoul National University Seoul, 08826 South Korea | |
| Phone | 82 7 0423 73415 |
| Website | cellid.co.kr |
Stock Details
| Ticker Symbol | 299660 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| ISIN Number | KR7299660001 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Yuil Kang Chang | Chief Executive Officer |